GNPXGenprex Inc
Mkt Cap
$7.2MVolume
215,839.0052W High
$117.5052W Low
$5.73PE Ratio
-0.06GNPX Fundamentals
Price
$5.77Prev Close
$6.27Open
$6.0850D MA
$11.13Beta
1.10Avg. Volume
367,498.88EPS (Annual)
-$266.95P/B
2.75Rev/Employee
$0.00Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules
Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market...
PR Newswire·4d ago
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and...
PR Newswire·4d ago
Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules
Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market...
PR Newswire·9d ago
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets...
PR Newswire·9d ago
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets...
PR Newswire·18d ago
Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System
Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System PR...
PR Newswire·9mo ago
Genprex Provides Update on Diabetes Gene Therapy Program
Genprex Provides Update on Diabetes Gene Therapy Program Genprex Provides Update on Diabetes Gene Therapy Program PR Newswire AUSTIN, Texas, Feb. 18, 2025 Signs an Amended & Restated License...
PR Newswire·9mo ago
Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer
Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer Genprex Collaborators Find NPRL2 Gene Therapy...
PR Newswire·9mo ago
Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa Gene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer
Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa Gene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer Genprex Announces...
PR Newswire·9mo ago
Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire AUSTIN, Texas, Jan. 6, 2025 AUSTIN...
PR Newswire·10mo ago